Baxter International, Inc. Completes Enrollment In Phase 3 Clinical Trial Of BAX 855, Extended Half-Life Recombinant FVIII For Hemophilia A

Published: Nov 13, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced it has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII (rFVIII) treatment for hemophilia A. The ongoing trial is aimed at assessing the efficacy of the compound in reducing annualized bleed rates (ABR) in both prophylaxis and on-demand treatment schedules, and will also evaluate its safety and pharmacokinetic profile.

Help employers find you! Check out all the jobs and post your resume.

Back to news